Mark A. Milad

1.3k citations

24 papers · 966 indexed · h-index 15

Surgery top 10%
Pharmacology top 2%
Endocrinology, Diabetes and Metabolism top 10%
Oncology
Rheumatology top 10%

Co-authors: William J. Jusko Elizabeth Ludwig Elliott Middleton Alan H. Jobe Kathleen A. Donovan James J. Ferry Thomas Peppard Alice Ke
Topics: Neonatal Respiratory Health Research (6 papers)Pharmacogenetics and Drug Metabolism (3 papers)Lipoproteins and Cardiovascular Health (3 papers)
Cited by: Pharmacology Endocrinology, Diabetes and Metabolism Rheumatology
Journals: SHILAP Revista de lepidopterologíaPLoS ONE Arteriosclerosis Thrombosis and Vascular Biology
Partner nations: United States Australia Singapore

In The Last Decade

Mark A. Milad

22 papers receiving 945 citations

Peers

Countries citing papers authored by Mark A. Milad

Since Specialization

Citations

This map shows the geographic impact of Mark A. Milad's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark A. Milad with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark A. Milad more than expected).

Fields of papers citing papers by Mark A. Milad

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark A. Milad. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark A. Milad. The network helps show where Mark A. Milad may publish in the future.

Co-authorship network of co-authors of Mark A. Milad

This figure shows the co-authorship network connecting the top 25 collaborators of Mark A. Milad. A scholar is included among the top collaborators of Mark A. Milad based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark A. Milad. Mark A. Milad is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Minimal physiologically‐based hybrid model of pharmacokinetics in pregnant women: Application to antenatal corticosteroids 2023 ·CPT Pharmacometrics & Systems Pharmacology ·Wojciech Krzyżański,Mark A. Milad,Alan H. Jobe,William J. Jusko	6
2	Respiratory benefit in preterm lambs is progressively lost when the concentration of fetal plasma betamethasone is titrated below two nanograms per milliliter 2023 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Erin L. Fee,Tsukasa Takahashi,Yuki Takahashi,(unknown),Michael W. Clarke,Mark A. Milad,Haruo Usuda,Hideyuki Ikeda,(unknown),(unknown),Demelza J. Ireland,John P. Newnham,Masatoshi Saito,Alan H. Jobe,Matthew W. Kemp	6
3	Pharmacokinetics of levonorgestrel and etonogestrel in rat or minipig following intravenous, subcutaneous, or intradermal administration 2022 ·Xenobiotica ·(unknown),Mark A. Milad,Louis L. Radulovic,(unknown)	1
4	Application of exposure bracketing to streamline the development of contraceptive products 2022 ·SHILAP Revista de lepidopterología ·Joshua D. Brown,Tamra Goodrow,Dan Hartman,Justin L. Hay,(unknown),Susan Hershenson,Douglas McNair,Bethany E. Matthews,Mark A. Milad,Stephan Schmidt,Kirsten M. Vogelsong,Ping Zhao	0
5	One percent of the clinical dose used for antenatal steroid therapy is sufficient to induce lung maturation when administered directly to the preterm ovine fetus 2022 ·American Journal of Physiology-Lung Cellular and Molecular Physiology ·Erin L. Fee,Tsukasa Takahashi,Yuki Takahashi,(unknown),Lucy L. Furfaro,Michael W. Clarke,Mark A. Milad,Haruo Usuda,John P. Newnham,Masatoshi Saito,Alan H. Jobe,Matthew W. Kemp	9
6	Tenofovir Alafenamide for HIV Prevention: Review of the Proceedings from the Gates Foundation Long-Acting TAF Product Development Meeting 2021 ·AIDS Research and Human Retroviruses ·Joseph Romano,Marc M. Baum,(unknown),(unknown),Charles Dobard,Paul L. Feldman,J. Gerardo Garcı́a-Lerma,Alessandro Grattoni,Manjula Gunawardana,(unknown),Thomas J. Hope,Ivana Massud,Mark A. Milad,John A. Moss,Fernanda P. Pons‐Faudoa,Shane Roller,Ariane van der Straten,Selvi Srinivasan,Ronald S. Veazey,(unknown)	19
7	Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women 2021 ·Journal of Pharmacokinetics and Pharmacodynamics ·Wojciech Krzyżański,Mark A. Milad,Alan H. Jobe,Thomas Peppard,Robert R. Bies,William J. Jusko	14
8	Oral dosing for antenatal corticosteroids in the Rhesus macaque 2019 ·PLoS ONE ·Augusto F. Schmidt,Matthew W. Kemp,Mark A. Milad,Lisa A. Miller,James P. Bridges,Michael W. Clarke,Paranthaman S. Kannan,Alan H. Jobe	14
9	Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus 2014 ·Arteriosclerosis Thrombosis and Vascular Biology ·María J. Gutiérrez,(unknown),Diane MacDougall,Jeffrey C. Hanselman,Janice R. Margulies,Poul Strange,Mark A. Milad,Scott McBride,Roger S. Newton	135
10	Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib 2014 ·Arthritis & Rheumatology ·Christina Charles‐Schoeman,Roy Fleischmann,Jean Davignon,Howard J. Schwartz,Scott Turner,Carine Beysen,Mark A. Milad,Marc K. Hellerstein,Zhen Luo,Irina V Kaplan,Richard J. Riese,Andrea Zuckerman,Iain B. McInnes	155
11	An association study of 43 SNPs in 16 candidate genes with atorvastatin response 2005 ·The Pharmacogenomics Journal ·John F. Thompson,M. Man,Keith Johnson,Linda S. Wood,Maruja E. Lira,David B. Lloyd,Poulabi Banerjee,Patrice M. Milos,(unknown),(unknown),Mark A. Milad,William J. Sasiela	165
12	Model-based development of gemcabene, a new lipid-altering agent 2005 ·The AAPS Journal ·Jaap W. Mandema,David Hermann,Wen‐Ping Wang,(unknown),Mark A. Milad,Rebecca Bakker‐Arkema,Daniel Hartman	53
13	UDP-GLUCURONOSYLTRANSFERASE 2B7 IS THE MAJOR ENZYME RESPONSIBLE FOR GEMCABENE GLUCURONIDATION IN HUMAN LIVER MICROSOMES 2005 ·Drug Metabolism and Disposition ·Jonathan Bauman,Theunis C. Goosen,Meera Tugnait,Vincent Peterkin,Susan Hurst,(unknown),Mark A. Milad,Michael H. Court,J. Andrew Williams	16
14	EFFECTS OF AVASIMIBE ON CYTOCHROME P450 2C9 EXPRESSION IN VITRO AND IN VIVO 2004 ·Drug Metabolism and Disposition ·Jasminder Sahi,Ralph H. Stern,Mark A. Milad,Kelly Rose,(unknown),Xianxian Zheng,(unknown),Nalini Sadagopan,Summer Jolley,Darryl Gilbert,Edward L. LeCluyse	19
15	Avasimibe Induces CYP3A4 and Multiple Drug Resistance Protein 1 Gene Expression through Activation of the Pregnane X Receptor 2003 ·Journal of Pharmacology and Experimental Therapeutics ·Jasminder Sahi,Mark A. Milad,Xianxian Zheng,Kelly Rose,Hongbing Wang,(unknown),Darryl Gilbert,Summer Jolley,Ralph H. Stern,Edward L. LeCluyse	55
16	Methylprednisolone pharmacokinetics and pharmacodynamics in chronic renal failure. 1995 ·PubMed ·William J. Jusko,Mark A. Milad,Elizabeth Ludwig,(unknown),R. Kohli	6
17	Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking 1994 ·Journal of Pharmacokinetics and Biopharmaceutics ·Mark A. Milad,Elizabeth Ludwig,(unknown),Elliott Middleton,William J. Jusko	31
18	Pharmacodynamic Interpretation of Adrenocorticotropin Stimulation Tests 1993 ·Annals of Pharmacotherapy ·Mark A. Milad,William J. Jusko	2
19	Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics 1993 ·Clinical Pharmacology & Therapeutics ·(unknown),Elizabeth Ludwig,Mark A. Milad,Kathleen A. Donovan,Elliott Middleton,James J. Ferry,William J. Jusko	133
20	Iron status in low‐birth‐weight infants, small and appropriate for gestational age. A follow‐up study 1992 ·Acta Paediatrica ·Manuel Olivares,S Llaguno,(unknown),Eva Hertrampf,(unknown),Mark A. Milad	30

About Mark A. Milad

Mark A. Milad is a scholar working on Pharmacology, Pediatrics, Perinatology and Child Health and Endocrinology, Diabetes and Metabolism, having authored 24 papers that have together received 966 indexed citations. Recurring topics across this work include Neonatal Respiratory Health Research (6 papers), Pharmacogenetics and Drug Metabolism (3 papers) and Lipoproteins and Cardiovascular Health (3 papers). The work is most often cited by research in Pharmacology (189 citations), Endocrinology, Diabetes and Metabolism (187 citations) and Rheumatology (143 citations). Mark A. Milad has collaborated with scholars based in United States, Australia and Singapore. Frequent co-authors include William J. Jusko, Elizabeth Ludwig, Elliott Middleton, Alan H. Jobe, Kathleen A. Donovan, James J. Ferry, Thomas Peppard, Alice Ke, Roger S. Newton and Janice R. Margulies. Their work appears in journals such as SHILAP Revista de lepidopterología, PLoS ONE and Arteriosclerosis Thrombosis and Vascular Biology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact